Study: NCT04333914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autophagy inhibitor (GNS651)
Description: Cohort 1 (arm B): 200mg q.d. orally for 10 consecutive days. If for any reason a treatment is not given within the allowed treatment window (± 12h) it will be cancelled (i.e., missed for that time point), and treatment will be resumed at the next dosing day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: In cohorts 1 and 2, patients allocated in the standard of care arms should receive best supportive care, as per the investigator's discretion and the local routine practices. With regards to the respiratory symptoms and medical resoures at investigational site, the following should be given according to the patient's condition: oxygen supplementation, non-invasive ventilation, invasive ventilation, antibiotherapy, vasopressor support, renal replacement therapy, or extracorporeal membrane oxygenation.~Additional care and medications should be administered in the patient's best interest.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: In cohorts 1 and 2, patients allocated in the standard of care arms should receive best supportive care, as per the investigator's discretion and the local routine practices. With regards to the respiratory symptoms and medical resoures at investigational site, the following should be given according to the patient's condition: oxygen supplementation, non-invasive ventilation, invasive ventilation, antibiotherapy, vasopressor support, renal replacement therapy, or extracorporeal membrane oxygenation.~Additional care and medications should be administered in the patient's best interest.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: In cohorts 1 and 2, patients allocated in the standard of care arms should receive best supportive care, as per the investigator's discretion and the local routine practices. With regards to the respiratory symptoms and medical resoures at investigational site, the following should be given according to the patient's condition: oxygen supplementation, non-invasive ventilation, invasive ventilation, antibiotherapy, vasopressor support, renal replacement therapy, or extracorporeal membrane oxygenation.~Additional care and medications should be administered in the patient's best interest.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: In cohorts 1 and 2, patients allocated in the standard of care arms should receive best supportive care, as per the investigator's discretion and the local routine practices. With regards to the respiratory symptoms and medical resoures at investigational site, the following should be given according to the patient's condition: oxygen supplementation, non-invasive ventilation, invasive ventilation, antibiotherapy, vasopressor support, renal replacement therapy, or extracorporeal membrane oxygenation.~Additional care and medications should be administered in the patient's best interest.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avdoralimab
Description: Cohorte 2 (arm H): 500mg, intravenously, at Day 1 then 200mg once daily every 2 days during 14 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monalizumab
Description: Cohorte 2 (arm G) : 50mg (flat dose),intravenously, single infusion at Day 1.